Randomized Trial of Hydroxychloroquine for Newly Diagnosed Chronic Graft-versus-Host Disease in Children: A Children's Oncology Group Study

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 1, 2012, Pages 84-91

  Gilman, Andrew L ^a   Schultz, Kirk R ^b   Goldman, Frederick D ^c   Sale, George E ^d   Krailo, Mark D ^e,f   Chen, Zhengjia ^g   Langholz, Bryan ^e,f   Jacobsohn, David A ^h   Chan, Ka Wah ⁱ   Ryan, Robin E ^j   Kellick, Michael ^k   Neudorf, Steven M ^l   Godder, Kamar ^m   Sandler, Eric S ⁿ   Sahdev, Indira ^o   Grupp, Stephan A ^p   Sanders, Jean E ^d   Wall, Donna A ^q  

^a Levine Children's Hospital   (United States)

^b BC CHILDREN S HOSPITAL   (Canada)

^c CHILDREN S HOSPITAL OF ALABAMA   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e CHILDREN S ONCOLOGY GROUP   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g EMORY UNIVERSITY   (United States)

^h CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

ⁱ TEXAS TRANSPLANT INSTITUTE   (United States)

^j CHILDREN S MERCY HOSPITAL   (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^m VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

ⁿ Nemour Children's Clinic   (United States)

^o SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^p CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^q UNIVERSITY OF MANITOBA   (Canada)

more..

Author keywords

Chronic graft versus host disease; GVHD; Hydroxychloroquine; Randomized

Indexed keywords

HYDROXYCHLOROQUINE; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; AVASCULAR NECROSIS; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; EYE TOXICITY; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; INFECTION; MALE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SCORING SYSTEM; TREATMENT RESPONSE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; GRAFT VS HOST DISEASE; HUMANS; HYDROXYCHLOROQUINE; INFANT; MALE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84855421339     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.05.016     Document Type: Article

References (31)

1. Gilman A.L., Serody J. Diagnosis and treatment of chronic GVHD. Semin Hematol 2006, 43:70-80.
2. Sullivan K.M., Witherspoon R.P., Storb R., et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988, 72:546-554.
3. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 2005, 11:945-955.
4. Shulman H.M., Kleiner D., Lee S.J., et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant 2006, 12:31-47.
5. Schultz K.R., Miklos D.B., Fowler D., et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. Biomarkers Working Group Report. Biol Blood Marrow Transplant 2006, 12:126-137.
6. Pavletic S., Martin P., Lee S.J., et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. Biol Blood Marrow Transplant 2006, 12:252-266.
7. Couriel D., Carpenter P.A., Cutler C., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006, 12:375-396.
8. Koc S., Leisenring W., Flowers M.E., et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002, 100:48-51.
9. Koc S., Leisenring W., Flowers M.E., et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 2000, 96:3995-3996.
10. Arora M., Wagner J.E., Davies S.M., et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001, 7:265-273.
11. Martin P.J., Storer B.E., Rowley S.D., et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood 2009, 113:5074-5082.
12. Martin P.J., Gilman A.L. Front line treatment of chronic graft versus host disease. Chronic Graft versus Host Disease: Interdisciplinary Management 2009, 124-133. Cambridge University Press, New York. G.B. Vogelsang, S.Z. Pavletic (Eds.).
13. Gilman A.L., Chan K.W., Mogul M., et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000, 6:327-334.
14. Ziegler H.K., Unanue E.R. Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci U S A 1982, 79:175-178.
15. Ertel W., Morrison M.H., Ayala A., Chaudry I.H. Chloroquine attenuates hemorrhagic shock-induced suppression of Kupffer cell antigen presentation and major histocompatibility complex class II antigen expression through blockade of tumor necrosis factor and prostaglandin release. Blood 1991, 78:1781-1788.
16. Sperber K., Quraishi H., Kalb T.H., Panja A., Stecher V., Mayer L. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. J Rheumatol 1993, 20:803-808.
17. Gilman A.L., Beams F., Tefft M., Mazumder A. The effect of hydroxychloroquine on alloreactivity and its potential use for graft-versus-host disease. Bone Marrow Transplant 1996, 17:1069-1075.
18. Goldman F.D., Gilman A.L., Hollenback C., Kato R.M., Premack R.A., Rawlings D.J. Hydroxychloroquine inhibitis calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood 2000, 95:3460-3466.
19. Schultz K.R., Nelson D., Bader S. Synergy between lysosomotropic amines and cyclosporin A on human T cell responses to an exogenous protein antigen, tetanus toxoid. Bone Marrow Transplant 1996, 18:625-631.
20. Schultz K.R., Bader S., Nelson D., Wang M.D., HayGlass K.T. Immune suppression by lysosomotropic amines and cyclosporine on T-cell responses to minor and major histocompatibility antigens: does synergy exist?. Transplantation 1997, 64:1055-1065.
21. Hsiao C.C., Su W.N., Forooghian F., et al. Evaluation for synergistic suppression of T cell responses to minor histocompatibility antigens by chloroquine in combination with tacrolimus and a rapamycin derivative, SDZ-RAD. Bone Marrow Transplant 2002, 30:905-913.
22. Zecca M., Prete A., Rondelli R., et al. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood 2002, 100:1192-1200.
23. 2 from contingency tables, and the calculation of P. J R Stat Soc B 1922, 85:87-94.
24. Fleiss J.L., Levin B., Paik M.C., et al. Statistical Methods for Rates and Proportions 2003, Wiley & Sons, Inc., New York.
25. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
26. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50:163-170.
27. Lee S.J., Vogelsang G., Flowers M.E. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003, 9:215-233.
28. She K., Gilman A.L., Aslanian S., et al. Altered TLR9 responses in circulating B cells at the onset of chronic GVHD. Biol Blood Marrow Transplant 2007, 13:386-397.
29. Fujii H., Cuvelier G., She K., et al. Biomarkers in newly diagnosed pediatric extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood 2008, 111:3276-3285.
30. Cuvelier G.D., Kariminia A., Fujii H., et al. Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children's Oncology Group Study, ASCT0031. Bone Marrow Transplant 2010, 45:1653-1657.
31. Cho B.S., Min C.K., Eom K.S., et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia 2009, 23:78-84.